Profil
Robert S.
Goodenow held several positions in the pharmaceutical industry, including Principal at Baxter International, Head-Oncology Business Development at Aventis, Secretary & Chief Business Officer at Syndax Pharmaceuticals, and Chief Business Officer at HUYA Bioscience International LLC.
He also served as Vice President-Corporate Development at Inovio Pharmaceuticals, Inc. from 2002 to 2007.
Goodenow received a doctorate from Stanford University and an undergraduate degree from the University of California, Berkeley.
Anciens postes connus de Robert Goodenow
| Sociétés | Poste | Fin |
|---|---|---|
| INOVIO PHARMACEUTICALS, INC. | Corporate Officer/Principal | 16/03/2007 |
HUYA Bioscience International LLC
 HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | President | - |
| BAXTER INTERNATIONAL INC. | Corporate Officer/Principal | - |
| Aventis, Inc. | Corporate Officer/Principal | - |
| SYNDAX PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formation de Robert Goodenow
| University of California, Berkeley | Undergraduate Degree |
| Stanford University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| INOVIO PHARMACEUTICALS, INC. | Health Technology |
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| BAXTER INTERNATIONAL INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
| Aventis, Inc. | |
HUYA Bioscience International LLC
HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Health Technology |